Home›Stock Screener›Jubilant Pharmova›Quarterly Results

Jubilant Pharmova Quarterly Results

Latest Quarter Net Profit
₹31 Cr
QSept 2026
Quarterly Results

Jubilant Pharmova quarterly results. In Sept 2026, Jubilant Pharmova (JUBLPHARMA) reported revenue ₹2,375 Cr and net profit ₹31 Cr — revenue +20.7% YoY. Also explore JUBLPHARMA price trends to track price trends across different timeframes.

JUBLPHARMA Quarterly Results — Revenue, Profit & EPS Highlights

Jubilant Pharmova latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View JUBLPHARMA 52-week high low for the annual high/low range and current price position.

  • Revenue of ₹2,375 Cr in Sept 2026 (+3.4% vs Mar 2026, +20.7% vs Sept 2025)
  • Net Profit of ₹31 Cr in Sept 2026 (-73.9% vs Mar 2026, -74.2% vs Sept 2025)
  • EBITDA of ₹245 Cr in Sept 2026 (-26.2% vs Mar 2026)
  • Operating Margin of 10.0% in Sept 2026 (-4.0pp vs Mar 2026)
  • Earnings Per Share of ₹1.97 in Sept 2026 (-73.9% vs Mar 2026)

Jubilant Pharmova Quarterly Results — Revenue, EBITDA, Net Profit & EPS

JUBLPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 2,375 2,296 2,241 1,968 1,928 3.4% 20.7%
Net Profit (₹ Cr) 31 119 56 120 151 - -
EBITDA (₹ Cr) 245 332 260 337 341 - -
EPS (₹) 1.97 7.55 3.57 7.59 9.71 - -
Operating Margin (%) 10.0% 14.0% 11.0% 17.0% 17.0% - -

JUBLPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results

Jubilant Pharmova 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Jubilant Pharmova share price screener.

Profitability Ratios

Profit Margin 1.3%
EBITDA Margin 10.3%
Operating Margin 10.0%
ROE (Annual) 1.7%

Balance Sheet Highlights

Total Assets ₹15,523 Cr
Total Equity ₹7,096 Cr
Current Assets ₹ Cr
Current Liabilities ₹5,888 Cr

Cash Flow Analysis

Operating Cash Flow ₹1,227 Cr
Investing Cash Flow ₹-1,143 Cr
Financing Cash Flow ₹95 Cr
Net Cash Flow ₹179 Cr

Current Market Data

Current Price ₹933.25
Exchange NSE
Last Updated Nov 19, 2026

JUBLPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Jubilant Pharmova latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores